title: The effect of androgen deprivation on malignant and benign prostate tissue.
abstract: The purpose of this research was to describe the changes in marker expression and histologic morphology following androgen deprivation in malignant and benign human prostates. Fourteen patients receiving pre-radical prostatectomy total androgen deprivation had pre- and post-androgen deprivation evaluation of marker expression and histologic morphology (both malignant and benign). Marker expression was significantly reduced for serum (p < 0.0001) and tissue (p < 0.004) PSA as well as bcl-2 expression (p < 0.008). There were significant histologic increases in vacuolization (p < 0.001), pyknosis (p < 0.04), fibrosis (p < 0.01) and lymphocytic infiltration (p < 0.008) in the malignant tissue. There were significant increases in squamous metaplasia (p < 0.0002), fibrosis (p < 0.0005), basal cell hypertrophy (p < 0.0005) and lymphocytic infiltration (p < 0.0002) in the benign tissue. Androgen deprivation therapy produces significant changes in marker expression and morphology in prostate specimens. At times these iatrogenic changes can be confusing. Clinicians and pathologists must be aware of these changes.
authors.affiliation: Hektoen Institute for Medical Research, Department of Urology of the University of Illinois School of Medicine, West Side Veterans' Administration Hospital, Chicago 60612, USA.
authors.forename: P
authors.initials: P
authors.lastname: Guinan
authors.forename: D
authors.initials: D
authors.lastname: Didomenico
authors.forename: J
authors.initials: J
authors.lastname: Brown
authors.forename: M
authors.initials: M
authors.lastname: Shaw
authors.forename: R
authors.initials: R
authors.lastname: Sharifi
authors.forename: V
authors.initials: V
authors.lastname: Ray
authors.forename: S
authors.initials: S
authors.lastname: Shott
authors.forename: M
authors.initials: M
authors.lastname: Rubenstein
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000097:blood; D005485:Flutamide / Q000627:therapeutic use; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy / Q000473:pathology; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D005485:Flutamide; D016729:Leuprolide